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Boca Raton Regional Hospital
• Not-for-profit 400 bed advanced academic tertiary medical center
• Recognized leader in: 
– Cardiovascular Care
– Oncology 
– Women’s Health  
– Orthopedics 
– Emergency Medicine 
– Neurosciences  
• Predominantly elderly patient population
• Highest ranked hospital in Palm Beach County 
– Listed by U.S. News & World Report 2019-2020
• Lynn Cancer Institute is one of the largest cancer programs in the state of Florida 
and accredited by the American College of Surgeons
Presentation Objective 
• Identify the benefits of utilizing a biosimilar compared 
to a reference product in patients at the Lynn Cancer 
Institute 
Erythropoietin-Stimulating Agents (ESAs)
ESAs
Chemotherapy 
induced anemia 
(CIA)
Chronic kidney 
disease (CKD)
Myelodysplastic 
syndromes 
(MDS)
Epoetin alfa [package insert]. Thousand Oaks, CA: Amgen; 2000.
Epoetin alfa-epbx [package insert]. Lake Forest, IL: Hospira; 2018. 
Introduction
A biosimilar is a biological product that is: 
• Highly similar to a reference product
• Contains no clinically meaningful differences in safety, purity, and 
potency compared to it’s reference product
The approval process does not require independent 
safety and efficacy analyses of the biosimilar 
Declerck P, Danesi R, Petersel D, Jacobs I. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects. Drugs. 2017;77(6):671–677. 
Introduction 
Epoetin alfa-epbx was FDA approved in May 2018
Therapeutic substitution between epoetin alfa and 
epoetin alfa-epbx has not been established 
In the Lynn Cancer Institute, patients were transitioned 
from epoetin alfa to epoetin alfa-epbx due to a cost 
savings initiative
Epoetin alfa-epbx [package insert]. Lake Forest, IL: Hospira; 2018. 
Previous Studies 
• Objective: Compare the safety and efficacy of epoetin alfa-epbx with 
epoetin alfa in patients with CKD on hemodialysis
• Methods: Phase 3, randomized, double-blind controlled trials 
• Patients: N=932
• 1º outcome: Difference between mean weekly hemoglobin levels and 
mean weekly dose 
• Results: Epoetin alfa-epbx demonstrated no clinically meaningful 
differences in efficacy compared to epoetin alfa
EPOE 10-13 (SC), EPOE 10-01 (IV)
Fishbane S, Spinwitz B, Wisemandle WA, et al. Randomized controlled trial of subcutaneous epoetin alfa-epbx versus epoetin alfa in end-stage kidney disease. Kidney Int Reports. 2019;4:1235-1247.   
Fishbane S, Singh B, Kumbhat S, Wisemandle WA, et al. Intravenous epoetin alfa-epbx versus epoetin alfa for treatment of end-stage kidney disease. Am Soc Nephrol. 2018;13:1204-1214. 
Purpose 
To analyze the effectiveness of epoetin 
alfa-epbx in maintaining hemoglobin levels 
in conditions that typically require ESAs
Study Design 
Inclusion Criteria
• Diagnosed with CIA, CKD, or MDS
• First dose and frequency of epoetin alfa-epbx
matched epoetin alfa dose and frequency
• Received a minimum of 5 months of therapy 
Exclusion Criteria
• Packed red blood 
cells or IV iron 
administration 
during the study 
period
Methods: Observational, retrospective, crossover study conducted at the Lynn 
Cancer Institute from January 2019 through May 2019
Transitioning Period 
Epoetin alfa 
treatment
• > 2 months 
of therapy
• > 3 doses 
March 2019
• Transitioned 
to an 
equivalent 
dosing 
regimen
Epoetin alfa-
epbx treatment
• > 2 months 
of therapy
• > 3 doses 
ICD-10 code 
generated 
report
Retrospective 
chart review  
Data 
recorded on 
Excel 
spreadsheet
Data Collection
Study Outcomes 
Primary 
Outcome 
• The mean difference between hemoglobin levels collected 
during epoetin alfa treatment and epoetin alfa-epbx treatment
Secondary 
Outcome 
• The rate of hemoglobin levels not maintained after 
transitioning from epoetin alfa to epoetin alfa-epbx, defined 
by an absolute difference of 1 g/dL
Results  
178 patients screened for 
inclusion
42 included in 
analysis 
CKD: 24MDS: 18
136 excluded
Results 
9.76
9.72
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Epoetin alfa
Epoetin alfa-epbx
Mean Hemoglobin Levels
Primary outcome: The mean difference between hemoglobin levels collected 
during epoetin alfa treatment and epoetin alfa-epbx treatment
Mean difference: 
0.04 g/dL 
T-test p value: 
0.5999
Results
12%
88%
Hgb not maintained Hgb maintained
Secondary outcome: The 
rate of hemoglobin levels not 
maintained after transitioning 
from epoetin alfa to epoetin 
alfa-epbx, defined by an 
absolute difference of 1 g/dL
Conclusion 
There was no statistically significant difference between 
hemoglobin levels after transitioning to epoetin alfa-epbx
Hemoglobin levels were not maintained in 5 out of 42 
(12%) patients after transitioning products 
• 4 patients experienced a decrease in Hg levels
• 1 patient experienced an increase in Hg levels 
Discussion
• In 3 out of 5 patients where hemoglobin levels were not 
maintained, disease progression was noted 
This trial demonstrates that transitioning to epoetin 
alfa-epbx is associated with similar hemoglobin 
levels in patients with CKD and MDS
Epoetin alfa-epbx is an efficacious agent for 
patients diagnosed with CKD or MDS 
Limitations
The disease states assessed are progressive conditions that 
require dose alteration and produce inconsistent laboratory values 
The data collection time frame limited the size of the study 
population increasing the variability of the results   
Results cannot be generalized to all patients receiving ESAs due 
to the specific patient population studied 
Limitations
The inclusion and exclusion criteria did not successfully 
capture patients diagnosed with CIA 
• Results would be predicted to be similar for this patient population  
The average rate of patients that do not normally maintain 
hemoglobin levels is unknown 
Self Assessment
Which of the following is not a benefit of utilizing a 
biosimilar?  Select all that apply.
Results in cost savings for both the institution and patient 
Are interchangeable with their prior reference product due to similar 
efficacy and safety 
Retain the same approval indications as their prior reference product 
Expand treatment options
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